ARCHIVES

NIH institute directors, in response to question from Sen. Arlen Specter, say Bush Administration’s stem cell research policy is harmful to NIH leadership in science.

This article is from The Cancer Letter archive.

Vol. 31 No. 14 | April 8, 2005

Download PDF Visit The Full Archive

Related Articles

Schilskly Promoted to Associate Dean At Chicago, Vogelzang To Direct Center

March 5, 1999

ACCP Publishes Guidelines Recommending Low-Dose CT

May 31, 2013

NIH Accepting FIRST Applications

May 2, 1986

In Brief: Deadline June 1 For Cancer Research Institute Grants; Chabner To Present Karnofsky Lecture

May 3, 1985

FDA unlikely to pull Iressa from market. Iressa a case study in how not to develop a drug, ODAC member says.

April 1, 2005

ImClone Offered C225 Deal To Seven Firms Prior To BMS

February 22, 2002